Menopause CSGUL
Menopause, perimenopause and ovarian failure
Hormonal changes associated with menopause
Describe signs and symptoms of menopause
Identify abnormal symptoms
When investigations are necessary
Long and short term treatments for menopause
Outline risks and benefits of HRT
Perimenopause:
Phase before menopause when ovaries gradually begin to produce less oestrogen. Irregular periods, erratic bleeding and larger gaps in between periods due to fluctuating hormone levels
Psychological symptoms and vasomotor symptoms like hot flushes, dryness and night sweats.
Menopause: 12 months after last menstrual period - loss of ovarian follicular function between 45-55
Premature ovarian failure: menopause under 40 and needs to be investigated and referred
Symptoms:
Endocrine system
Hot flashes
Night sweats
Irregular periods
Reproductive system
Dryness
Decreased libido
Breast soreness
Nervous system
Mood changes
Sleep disturbances
Memory issues
Urinary system
Frequent urination
Recurrent UTIs
Prolapse
Musculoskeletal
Joint pain
Osteoporosis
GI
Bloating
Digestive changes
Menstrual cycle:
Hypothalamus produces GnRH to stimulate production of FSH from pituitary gland
FSH stimulates follicular development in ovary and promotes ovarian oestrogen production
Increases oestrogen suppress FSH and trigger mid cycle LH surge = ovulation
End of luteal = no conception then oestrogen drops + progesterone and menstruation happens
Perimenopause:
Oestrogen fluctuates and decreases = more FSH to be released so more oestrogen is released by ovaries
Ovaries become less responsive due to reduced number of follicles
FSH 4.7-21.5IU/L
LH 1.9-12.5IU/L
Oestrogen 30-400pg/ml
Menopause:
Oestrogen is low as ovaries are producing minimal oestrogen
Causing high level of FSH to try and increase stimulation of follicles and oestrogen but there is lack of follicle so oestrogen remains low
Role of hormones:
Progesterone
Prepares uterus lining for pregnancy
Maintains pregnancy by supporting developing foetus
Supports breast development for milk
Helps maintain bone health
Oestrogen:
Regulates menstrual cycle and ovulation
Maintains bone density
Supports cardiovasc health by maintaining healthy cholesterol levels
Promote skin elasticity and moisture
Influences mood and cognitive function
Supports reproductive tissue e.g., vaginal lubrication, breast development
Menopause:
Ageing ovary has less ooctyes and is less responsive to gonadotrophins -> oestrogen declines
Low oestrogen persisting = stimulate hpa to produce more fsh to make residual oocytes ovulate
Ovarian dysfunction is a gradual process -> marked by erratic hormonal changes and sporadic ovulation where FSH levels can fluctuate.
By menopause -> complete ovarian failure then there is consistently raised FSH
To diagnose menopause -> use clinical hisotry, symptoms and absence of period of 12months, we do not check bloods
Check FSH if pt is under 40, 40-45 with menopausal or is over 50 and using POP.
Post menopausal risks:
Osteoporosis - thinner and weaker bones due to low oestrogen
Cardiovasc decline - decreased oestrogen has increased heart disease and stroke
Vaginal atrophy - thinner and less elastic so there is increased risk of infection
Increased uti - due to thin walls from lack of oestrogen so increased risk of infection
Sleep disturbances - decreased oestrogen decreases serotonin
Perimenopause diagnosis:
Clinical history - cycle info
Reduced flow of blood
Shorter no. of days
Bigger gaps in between periods
Red flag:
Intermenstrual bleeding
Post coital bleeding
Menorrhagia
Post menopausal bleeding
Rule out endometrial cancer - refer to transvaginal ultrasound scan
Unexpected weight loss
Severe joint pain
Persistent fever
Non hormonal treatment:
Ssri, gabapentin or clonidine to reduce hot flushes and mood swings
Balanced diet, reg exercise and stress management to improve overall wellbeing
Phytoestrogens, black cohosh and vit E to mimic oestrogen and reduce hot flashes
Acupuncture/hypnotherapy for hot flushes
Vaginal moisturisers and lubricants to relieve dryness and discomfort
HRT:
Oestrogen and progesterone
Oral tabs, patches, gels and sprays
To improve symptoms, bone density and reduce heart disease risk
Small risk of breast cancer with combines HRT, oestrogen only has little to no risk
Indication: provide relief of menopausal symptoms, prevent osteoporosis, maintain quality of life, premature ovarian failure, surgical or radiation menopause
Contraindications to HRT:
Current, past or suspected breast cancer
Known or suspected oestrogen dependent cancer
Undiagnosed vaginal bleeding
Untreated endometrial hyperplasia
Previous idiopathic or current venous thromoembolism (unless on anticoags)
Active liver disease with abnormal lfts
Pregnancy
Thrombophilic disorder
Uterus:
Combined HRT -> oestrogen + progesterone. Oral tablets, patches, gels, sprays. Progesterone needed to protect uterine lining from hyperplasia and cancer
Sequential combined HRT -> oestrogen and progesterone cyclic - oral tabs and patches with monthly bleeding for perimenopausal women
Continuous combined HRT -> oestrogen and progeston oral tabs, patches, gels, sprays no monthly bleeding for post menopausal women
Local oestrogen - vaginal symptoms
w/o uterus:
Oestrogen only
Local oestrogen
Monitoring HRT:
Review after 3 months starting treatment
Review annually afterwards
Cover symptom control, ongoing indication, side effects and bleeding
Check bmi and bp
Reinforce healthy lifestyle advice
Ensure cervical and breast screening
Explain that HRT is not the same as contraception and to change to COC/POP if wants contraception but risk is low due to age
Testosterone
Topical testosterone used for patients with low sexual desire with menopause
Usually if HRT is ineffective
Monitor testosterone levels
Check for side effects like hair, acne, weight gain, alopecia, voice changes and clitoral enlargement
Refer:
Severe menopause symptoms
Contraindications to HRT
Premature ovarian failure
Complex medical history
Uncertainty of treatment
QUESTIONS:
Part 1: Single Best Answer (SBA) Questions
1.
A 48-year-old woman presents with a 6-month history of increasingly irregular periods and debilitating hot flushes. What is the most appropriate initial approach to diagnosis?
a) Order an FSH level to confirm she is perimenopausal.
b) Diagnose perimenopause based on her clinical history and symptoms.
c) Refer her for a transvaginal ultrasound scan.
d) Start her on combined HRT immediately and review in 3 months.
Answer:
b) Diagnose perimenopause based on her clinical history and symptoms.
In women over 45, perimenopause is a clinical diagnosis. FSH testing is not routinely indicated as levels fluctuate. Treatment can be discussed, but a diagnosis should be established first.
2.
A 52-year-old woman who had a total hysterectomy (for fibroids) 5 years ago presents with severe hot flushes. She has no personal history of breast cancer or VTE. What is the most appropriate form of HRT for her?
a) Sequential combined HRT
b) Continuous combined HRT
c) Oestrogen-only HRT
d) Testosterone gel
Answer:
c) Oestrogen-only HRT
As she has no uterus, there is no risk of endometrial hyperplasia or cancer. Therefore, she does not require the protective progestogen component and can use oestrogen-only HRT, which has a simpler risk profile.
3.
Which of the following is an absolute contraindication to initiating HRT?
a) A family history of breast cancer.
b) Controlled hypertension.
c) Undiagnosed post-menopausal bleeding.
d) A history of migraine without aura.
Answer:
c) Undiagnosed post-menopausal bleeding.
Undiagnosed vaginal/post-menopausal bleeding is an absolute contraindication as it must be investigated to rule out endometrial cancer before starting HRT. A family history (a) is not a contraindication. Migraine without aura (d) and controlled hypertension (b) require caution but are not absolute contraindications.
4.
A 58-year-old woman, 8 years post-menopause, is on continuous combined HRT. During her annual review, she asks about the risk of breast cancer. What is the most accurate information to give her?
a) All forms of HRT significantly increase the risk of breast cancer from the first year of use.
b) Oestrogen-only HRT carries a significant risk, but combined HRT does not.
c) There is a small increased risk with combined HRT, which is related to the duration of use.
d) HRT actually protects against breast cancer.
Answer:
c) There is a small increased risk with combined HRT, which is related to the duration of use.
The risk of breast cancer is primarily associated with combined HRT (oestrogen and progestogen) and increases with duration of use. The risk reduces after stopping and returns to baseline around 5 years later. Oestrogen-only HRT has little to no increased risk.
Part 2: Extended Matching Questions (EMQ)
Questions 5-7:
For each patient scenario, select the MOST appropriate management option.
Options:
A. Recommend lifestyle changes and a trial of a vaginal moisturiser.
B. Prescribe sequential combined HRT.
C. Prescribe continuous combined HRT.
D. Prescribe oestrogen-only HRT.
E. Refer to gynaecology for investigation.
5.
A 49-year-old woman with irregular periods and hot flushes. She has a uterus and her last period was 6 weeks ago.
Answer:
B. Prescribe sequential combined HRT.
She is perimenopausal (irregular periods) and has a uterus. Sequential HRT provides oestrogen with cyclical progestogen to induce a regular withdrawal bleed and protect the endometrium.
6.
A 60-year-old woman who had her last period 10 years ago. She has a uterus and presents with distressing vaginal dryness and hot flushes.
Answer:
C. Prescribe continuous combined HRT.
She is postmenopausal (>1 year since last period) and has a uterus. Continuous combined HRT is appropriate as it should not cause bleeding and provides symptom relief.
7.
A 55-year-old woman presents with a 3-week history of post-menopausal bleeding. She is not on HRT.
Answer:
E. Refer to gynaecology for investigation.
Post-menopausal bleeding is a red flag for endometrial cancer until proven otherwise and requires urgent investigation (e.g., ultrasound, biopsy), not initiation of HRT.
Part 3: Clinical Scenarios (OSCE/Patient Style)
Scenario 1: HRT Counselling
A 51-year-old woman with a uterus seeks advice for hot flushes. She is interested in HRT but is worried about the risk of breast cancer, which her mother had. She has no personal history of cancer or VTE.
How do you counsel this patient?
Acknowledge Concerns: "It's very understandable to be worried about breast cancer, especially with a family history. It's important to know that for most women, the benefits of HRT outweigh the risks."
Explain the Risk Accurately: "The small increased risk of breast cancer is primarily linked to the combined form of HRT (which contains oestrogen and progesterone) and is related to how long you take it. For a woman in her 50s, the absolute risk is small. For example, it might mean a few extra cases per 1000 women after 5+ years of use. This risk decreases after you stop HRT."
Discuss Benefits & Alternatives: "HRT is the most effective treatment for your symptoms and also helps prevent osteoporosis. If you're still concerned, we could consider oestrogen-only HRT, which has little to no increased risk, but that's only an option if you've had a hysterectomy. We can also discuss non-hormonal options, though they are less effective."
Safety Netting: "We would start you on the lowest effective dose and review you regularly. It's also crucial that you continue with your routine breast screening appointments."
Scenario 2: Differentiating Treatments
A 58-year-old postmenopausal woman on continuous combined HRT for 4 years reports that her hot flushes are well controlled, but she is very bothered by persistent vaginal dryness and discomfort during intercourse.
What is the most appropriate management?
Assess Current Regimen: "It's great that the HRT patch is controlling your flushes. The vaginal symptoms can sometimes persist even with systemic HRT because the dose needed for the whole body isn't always high enough to fully treat the local tissues in the vagina."
Recommend Additional Treatment: "The most effective solution for this is to add a local vaginal oestrogen treatment, such as a cream, pessary, or ring. This delivers a low dose of oestrogen directly to the vaginal area, which is very safe and will effectively treat the dryness without significantly increasing your overall hormone levels."
Reassure on Safety: "Using local oestrogen in addition to your existing HRT is safe and is recommended in this situation. It can be used long-term to maintain comfort and vaginal health."
Part 4: Prescription & Monitoring
Question 8: Formulation Choice
A 53-year-old woman with a history of hypertension (well-controlled) and a BMI of 35 requests HRT for hot flushes. She has a uterus. Why might a transdermal HRT preparation (patch/gel) be preferred for her over an oral preparation?
Answer:
Transdermal HRT is preferred because it is associated with a lower risk of Venous Thromboembolism (VTE). This patient has two additional risk factors for VTE (hypertension and high BMI), so avoiding the VTE risk associated with oral HRT is a prudent safety measure.
Question 9: Contraception Advice
A 48-year-old perimenopausal woman who smokes is started on sequential combined HRT. She is sexually active and does not wish to become pregnant. What advice must you give her regarding contraception?
Answer:
"It is very important to know that HRT is not a form of contraception. The hormone doses in HRT do not reliably prevent ovulation. Therefore, you will need to use a reliable contraceptive method until you are confirmed to be post-menopausal (i.e., until you are 55 years old, or have had no natural periods for 2 years if you are under 50). Given that you smoke, a progesterone-only method like the mini-pill, implant, or coil would be suitable, as the combined oral contraceptive pill is contraindicated."